Emma Grundtvig Gram

Ms. Emma Grundtvig Gram

Section of General Practice, Faculty of Health and Medicine, University of Copenhagen, Copenhagen, Hovedstaden, Denmark
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in BMJ Evidence-Based Medicine
Verified
Journal Article
Closed access
PDF file
MBMille Falk Bjørch
Mille Falk Bjørch
Emma Grundtvig GramEmma Grundtvig Gram
Emma Grundtvig Gram
JBJohn Brandt Brodersen
John Brandt Brodersen
Objectives We aimed to systematically identify and scrutinise published empirical evidence about overdiagnosis in malignant melanoma and examine how frequent overdiagnosis of melanoma is and whether this is related to different types of interventions or diagnostic technologies. Design and setting Empirical studies that discussed overdiagnosis in malignant melanoma were eligible, including qualitative and quantitative studies in any type of population, age group and geographical location. We excluded studies that did not include empirical data, studies that only mentioned ‘overdiagnosis’ without addressing it further and studies that used the term overdiagnosis for cases of misdiagnosis or false positives. We developed the search strategy in cooperation with an information specialist. We searched five databases on 21 April 2022: MEDLINE, Embase, CINAHL, PsycINFO and Cochrane Library. This scoping review adheres to The JBI methodology and Prefered Reporting Items for Systematic Reviews and Meta-analyses extension for Scoping reviews (PRISMA-ScR). Two reviewers independently screened titles, abstracts and full texts for inclusion and extracted data from the included studies. The data extracted include study characteristics, population details, research question, the context and the study’s main results. Results Our search resulted in 1134 potentially relevant studies. 35 studies were included: 29 register studies, 3 cohort studies, 1 case–control study, 1 survey study and 1 randomised controlled trial. Most register studies examined trends in melanoma incidence and/or mortality and found a significant increase in incidence between 0.39% and 6.6% annually and a little or no increase in mortality. Three cohort studies and one case–control study showed that skin screening was associated with increased detection of melanoma; especially in situ or thin invasive melanoma. Three studies estimated the degree of overdiagnosis which ranged from 29% to 60%. Conclusions Epidemiological data suggest a high degree of overdiagnosis in malignant melanoma. Studies that examined the association between skin screening and malignant melanoma all found increased detection of melanomas, mostly thin and in situ melanomas, which raises concern about overdiagnosis.

26 April 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
Emma Grundtvig GramEmma Grundtvig Gram
Emma Grundtvig Gram
VSVolkert Siersma
Volkert Siersma
JBJohn Brandt Brodersen
John Brandt Brodersen
Objective To compare the long-term psychosocial consequences of mammography screening among women with breast cancer, normal results and false-positive results. Design A matched cohort study with follow-up of 12–14 years. Setting Denmark from 2004 to 2019. Participants 1170 women who participated in the Danish mammography screening programme in 2004–2005. Intervention Mammography screening for women aged 50–69 years. Outcome measures We assessed the psychosocial consequences with the Consequences Of Screening–Breast Cancer, a condition-specific questionnaire that is psychometrically validated and encompasses 14 psychosocial dimensions. Results Across all 14 psychosocial outcomes, women with false-positive results averagely reported higher psychosocial consequences compared with women with normal findings. Mean differences were statistically insignificant except for the existential values scale: 0.61 (95% CI (0.15 to 1.06), p=0.009). Additionally, women with false-positive results and women diagnosed with breast cancer were affected in a dose–response manner, where women diagnosed with breast cancer were more affected than women with false-positive results. Conclusion Our study suggests that a false-positive mammogram is associated with increased psychosocial consequences 12–14 years after the screening. This study adds to the harms of mammography screening. The findings should be used to inform decision-making among the invited women and political and governmental decisions about mammography screening programmes.

31 October 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IKIsabella Skaarup Kindt
Isabella Skaarup Kindt
FMFrederik Handberg Juul Martiny
Frederik Handberg Juul Martiny
Emma Grundtvig GramEmma Grundtvig Gram
Emma Grundtvig Gram
ABAnne Katrine Lykke Bie
Anne Katrine Lykke Bie
CJChristian Patrick Jauernik
Christian Patrick Jauernik
JBJohn Brandt Brodersen
John Brandt Brodersen
Introduction: Physical harm from Colorectal Cancer Screening tends to be inadequately measured and reported in clinical trials. Also, studies of ongoing Colorectal Cancer Screening programs have found more frequent and severe physical harm from screening procedures, e.g., bleeding and perforation, than reported in previous trials. Therefore, the objectives of the study were to systematically review the evidence on the risk of bleeding and perforation in Colorectal Cancer Screening. Design: Systematic review with descriptive statistics and random-effects meta-analyses. Methods: We systematically searched five databases for studies investigating physical harms related to Colorectal Cancer Screening. We assessed the internal and the external validity using the ROBINS-I tool and the GRADE approach. Harm estimates was calculated using mixed Poisson regression models in random-effect meta-analyses. Results: We included 89 studies. Reporting and measurement of harms was inadequate in most studies. In effect, the risk of bias was critical in 97.3% and serious in 98.3% of studies. All GRADE ratings were very low. Based on severe findings with not-critical risk of bias and 30 days follow-up, the risk of bleedings per 100,000 people screened were 8 [2;24] for sigmoidoscopy, 229 [129;408] for colonoscopy following fecal immunochemical test, 68 [39;118] for once-only colonoscopy, and 698 [443;1045] for colonoscopy following any screening tests. The risk of perforations was 88 [56;138] for colonoscopy following fecal immunochemical test and 53 [25;112] for once-only colonoscopy. There were no findings within the subcategory severe perforation with long-term follow-up for colonoscopy following any screening tests and sigmoidoscopy. Discussion: Harm estimates varied widely across studies, reporting and measurement of harms was mostly inadequate, and the risk of bias and GRADE ratings were very poor, collectively leading to underestimation of harm. In effect, we consider our estimates of perforation and bleeding as conservative, highlighting the need for better reporting and measurement in future studies. Trial registration: PROSPERO registration number: CRD42017058844.

5 October 2025 in BMJ Evidence-Based Medicine
Verified
Journal Article
Open access
PDF file
Emma Grundtvig GramEmma Grundtvig Gram
Emma Grundtvig Gram
RMRay Moynihan
Ray Moynihan
Tessa CoppTessa Copp
Tessa Copp
PSPatti Shih
Patti Shih
LALoai Albarqouni
Loai Albarqouni
Brooke NickelBrooke Nickel
Brooke Nickel
Background Misleading information about medical products on social media may cause overuse. Objectives Explore interventions targeting the problem of misleading medical information and marketing on social media, with a focus on preventing medical overuse including overdiagnosis. Eligibility criteria We included peer-reviewed studies with original data on an intervention targeting misleading medical information on social media and governmental/institutional responses with and without evaluation. We excluded responses relating to COVID-19. Sources of evidence four electronic databases: MEDLINE/PubMed, PsycINFO, Academic Search Complete and Web of Science, and searches of grey literature on Google and Google Scholar. Search date: 9 June 2025. Data charting We used prespecified data forms populated in duplicate by two reviewers. Results We identified 27 peer-reviewed articles and 25 organisational and governmental responses (grey literature). 20 (74%) of the peer-reviewed interventions targeted the consumer to enhance ‘media literacy’, support decision-making or warn about misinformation trends. Approaches included education, such as videos or information materials, to improve detection of misinformation, as well as correcting misinformation and rebutting claims. Only two (7.4%) of the peer-reviewed approaches were sensitive to the problem of medical overuse: a risk-of-deception tool and an informed decision-making service. The grey literature about government and organisational responses chiefly comprised general advertising regulations and other educational resources for consumers to identify and navigate misinformation. The advertising regulations ranged from self-regulatory codes of practice to mandatory regulations, requiring pre-approval of social media marketing material. Most regulations stated advertising should be truthful, presenting both benefits and harms and not be misleading. Most of the grey literature (64%) was sensitive to medical overuse, though none referred explicitly to the problem. Conclusions Current efforts to address misleading medical marketing on social media often overlook the critical issue of medical overuse and fail to provide sufficient consumer protections in this rapidly evolving digital landscape of social media, such as the speed of dissemination, reach and the role of third-party advertising. These gaps in research, regulation and practice present significant opportunities to strengthen evidence-based policies and public health responses. Trial registration details https://doi.org/10.17605/OSF.IO/2NJSH

17 February 2023 in Health Expectations
Verified
Journal Article
Open access
Emma Grundtvig GramEmma Grundtvig Gram
Emma Grundtvig Gram
SKSigrid W. Knudsen
Sigrid W. Knudsen
JBJohn Brandt Brodersen
John Brandt Brodersen
AJAlexandra Brandt Brandt Ryborg Jønsson
Alexandra Brandt Brandt Ryborg Jønsson
IntroductionIn Denmark, women are discontinued from mammography screening at age 69 due to decreased likelihood of benefits and increased likelihood of harm. The risk of harm increases with age and includes false positives, overdiagnosis and overtreatment. In a questionnaire survey, 24 women expressed unsolicited concerns about being discontinued from mammography screening due to age. This calls for further investigation of experiences related to discontinuation from screening. MethodsWe invited the women, who had left comments on the questionnaire, to participate in in-depth interviews with the purpose to explore their reactions, preferences, and conceptions about mammography screening and discontinuation. The interviews lasted 1-4 h and were followed up with a telephone interview 2 weeks after the initial interview. ResultsThe women had high expectations of the benefits of mammography screening and felt that participation was a moral obligation. Following that, they perceived the screening discontinuation as a result of societal age discrimination and consequently felt devalued. Further, the women perceived the discontinuation as a health threat, felt more susceptible to late diagnosis and death, and therefore sought out new ways to control their risk of breast cancer. ConclusionOur findings indicate that the age-related discontinuation from mammography screening might be of more importance than previously assumed. This study raises important questions about screening ethics, and we encourage research to explore this in other settings. Patient and Public ContributionThis study was conducted as a result of the women's unsolicited concerns about being discontinued from screening. This particular group contributed to the study with their own statements, interpretations and perspectives on the discontinuation of screening, and the initial analysis of data was discussed with the women during follow-up interviews.

1 March 2023 in Patient Related Outcome Measures
Verified
Journal Article
Open access
PDF file
Emma Grundtvig GramEmma Grundtvig Gram
Emma Grundtvig Gram
JRJessica Á Rogvi
Jessica Á Rogvi
AAAnders Heiberg Agerbeck
Anders Heiberg Agerbeck
FMFrederik Martiny
Frederik Martiny
ABAnne Katrine Lykke Bie
Anne Katrine Lykke Bie
JBJohn Brandt Brodersen
John Brandt Brodersen
Objective: This systematic review aimed to assess the adequacy of measurement properties in Patient-Reported Outcome Measures (PROMs) used to quantify psychosocial consequences of colorectal cancer screening among adults at average risk. Methods: We searched four databases for eligible studies: MEDLINE, CINAHL, PsycINFO, and Embase. Our approach was inclusive and encompassed all empirical studies that quantified aspects of psychosocial consequences of colorectal cancer screening. We assessed the adequacy of PROM development and measurement properties for content validity using The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) risk of bias checklist. Results: We included 33 studies that all together used 30 different outcome measures. Two PROMs (6.7%) were developed in a colorectal cancer screening context. COSMIN rating for PROM development was inadequate for 29 out of 30 PROMs (97%). PROMs lacked proper cognitive interviews and pilot studies and therefore had no proven content validity. According to the COSMIN checklist, 27 out of 30 PROMs (90%) had inadequate measurement properties for content validity. Discussion: The majority of included PROMs had inadequate development and measurement properties. These findings shed light on the trustworthiness of the included studies’ findings and call for reevaluation of existing evidence on the psychosocial consequences of colorectal cancer screening. To provide trustworthy evidence about the psychosocial consequences of colorectal cancer screening, editors could require that studies provide evidence of the methodological quality of the PROM. Alternatively, authors should transparently disclose their studies’ methodological limitations in measuring psychosocial consequences of screening validly.